September 16, 2025 a 09:01 am
DGX: Analysts Ratings - Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, a leader in diagnostic testing and information services, has shown a nuanced trend in analyst recommendations. As of September 2025, analysts present a balanced outlook with a predominant inclination towards 'Hold', indicating a cautious sentiment amidst market fluctuations. With innovations and expansions in their diagnostic services, the company's future remains a focal interest for analysts.
Historical Stock Grades
In September 2025, Quest Diagnostics exhibits a persistent 'Hold' sentiment among analysts. The current rating distribution underscores a conservative approach, prioritizing stability over aggressive positioning. Here's the detailed overview:
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 7 | |
| Hold | 10 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment for Quest Diagnostics over the past months has been consistent, with a strong tendency towards a 'Hold' rating. The stable number of 'Hold' ratings signifies a wait-and-see approach among investors:
- Consistent 'Hold' ratings indicating market caution.
- Marginal decrease in 'Buy' ratings from August to September 2025.
- No notable changes in 'Sell' or 'Strong Sell', highlighting stable market attitudes.
Percentage Trends
Analyzing the percentage trends over the last months reveals a shift towards more conservative ratings, with 'Hold' gradually taking precedence:
- 'Strong Buy' has maintained low levels, reflecting limited high-confidence buying opportunities since mid-2023.
- 'Buy' ratings saw a slight decline, indicating more cautious optimism.
- 'Hold' ratings have consistently represented roughly 50% of the total, indicating a non-committal market stance.
- The shift towards neutral and conservative ratings points to a stable yet cautious outlook among analysts.
Latest Analyst Recommendations
Recent recommendations highlight a tendency towards maintaining current ratings, with some downgrades reflecting a cautious market approach:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-25 | Neutral | Outperform | Baird |
| 2025-07-23 | Neutral | Neutral | UBS |
| 2025-07-23 | Hold | Hold | Truist Securities |
| 2025-07-23 | Hold | Hold | Deutsche Bank |
| 2025-07-18 | Neutral | Neutral | UBS |
Analyst Recommendations with Change of Opinion
The following table reflects recommendations with a change in opinion, indicating shifting perspectives among analysts:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-25 | Neutral | Outperform | Baird |
| 2025-03-04 | Neutral | Buy | Citigroup |
| 2025-01-06 | Outperform | Market Perform | Leerink Partners |
| 2024-12-17 | Overweight | Equal Weight | Morgan Stanley |
| 2024-10-23 | Outperform | Neutral | Baird |
Interpretation
The current sentiment around Quest Diagnostics indicates caution with a steady leaning on 'Hold' recommendations, suggesting that the market remains indecisive about the near-term prospects of the stock. The stability in analyst ratings echoes a neutral sentiment, with neither significant optimism nor pessimism prevalent. While downgrades by major analysts like Baird point to potential reservations about growth, upgrades still signify pockets of confidence in the company's strategies and market positioning. Collectively, this suggests a stable but vigilant analyst viewpoint.
Conclusion
Quest Diagnostics Incorporated sees a cautious analyst stance, primarily led by 'Hold' recommendations. Cautious optimism and strategic improvements underscore potential growth, yet market uncertainties necessitate prudent analysis. As the diagnostics sector evolves, DGX remains crucial in sector-leader aspirations despite conservative recommendations. Analysts are aligned in a balanced perspective, reflecting Quest's strong market presence coupled with calculated growth prospects.